Skip to content

Novocure

US · NVCR #2889 by market cap Listed 2015
10.71 +0.02 +0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 19 in the most recent period (2026/Q3).
  • Total institutional ownership fell 2.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
89.17% -2.41pp
Institutions
291 +19
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund59.73%
Hedge Fund15.93%
Public Company9.06%
Individual/Insider8.66%
Private Company1.66%
Government Pension Fund1.60%
Insurance Company0.94%
VC/PE Fund0.12%
Family Office/Trust0.12%
Other2.18%

Top holders as of 2026-09-30

FMR 14.86% · 17.38M sh
BlackRock 10.15% · 11.86M sh
Soleus Capital Management, L.P. 8.06% · 9.43M sh
Hansjoerg Wyss 6.96% · 8.14M sh
Vanguard Portfolio Management, LLC 5.55% · 6.49M sh
Vanguard Capital Management, LLC 4.21% · 4.92M sh
Morgan Stanley 4.02% · 4.70M sh
State Street Global Advisors 2.50% · 2.93M sh
Geode Capital Management, LLC 2.40% · 2.81M sh
Wells Fargo & Company 2.16% · 2.53M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 19 sells

NameRoleStake
Hansjoerg Wyss Former Director 6.96%
William Doyle Executive Chairperson 0.46%
Asaf Danziger Director 0.19%
William Vernon Lead Independent Director 0.17%
Uri Weinberg Chief Innovation Officer & Chief Medical Officer 0.13%
Frank Leonard Chief Executive Officer 0.13%
Ashley Cordova Former Chief Executive Officer 0.11%
Barak Ben-Arye General Counsel 0.11%
Michael Puri Chief Human Resources Officer 0.09%
Kinyip Leung Independent Director 0.08%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-08 Christoph Brackmann Chief Financial Officer Open Market Disposition -7,343 $12.86
2026-11-08 Mukund Paravasthu Chief Operating Officer Open Market Disposition -3,079 $12.86
2026-11-01 Michael Puri Chief Human Resources Officer Open Market Disposition -660 $13.24
2026-06-29 Asaf Danziger Director Other Acquisition +268 $11.15
2026-06-29 Frank Leonard Chief Executive Officer Other Acquisition +1,905 $11.15
2026-06-29 Michael Puri Chief Human Resources Officer Other Acquisition +1,905 $11.15
2026-06-29 Barak Ben-Arye General Counsel Other Acquisition +1,299 $11.15
2026-06-03 Frank Leonard Chief Executive Officer Open Market Disposition -34,273 $17.93
2026-06-02 Jeryl Hilleman Independent Director Other Acquisition +11,610 --
2026-06-02 Jeryl Hilleman Independent Director Other Derivative Acquisition +16,999 $16.15
2026-06-02 David Hung Independent Director Other Acquisition +11,610 --
2026-06-02 David Hung Independent Director Other Derivative Acquisition +16,999 $16.15
2026-06-02 Timothy Scannell Former Independent Director Other Acquisition +11,610 --
2026-06-02 Timothy Scannell Former Independent Director Other Derivative Acquisition +16,999 $16.15
2026-06-02 Kinyip Leung Independent Director Other Acquisition +11,610 --
2026-06-02 Kinyip Leung Independent Director Other Derivative Acquisition +16,999 $16.15
2026-06-02 William Vernon Lead Independent Director Other Acquisition +11,610 --
2026-06-02 William Vernon Lead Independent Director Other Derivative Acquisition +16,999 $16.15
2026-06-02 Martin Madden Independent Director Other Acquisition +11,610 --
2026-06-02 Martin Madden Independent Director Other Derivative Acquisition +16,999 $16.15

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Novocure discussion 0 comments

Add a comment